Monopar Therapeutics Inc. (MNPR) Misses Q3 EPS by 27c
Tweet
Share
E-mailGet Alerts MNPR Hot Sheet
Join SI Premium – FREE
Monopar Therapeutics Inc. (NASDAQ: MNPR) reported Q3 EPS of ($0.37), $0.27 worse than the analyst estimate of ($0.10).
For earnings history and earnings-related data on Monopar Therapeutics Inc. (MNPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
- Zhipu AI prices HK offering at HK$1,588/share - Reuters
- Us Military Completes Another Round Of Strikes Against Iran - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
